Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional

BIBTEX RIS

Laboratory profiles of patients hospitalized with COVID-19 pneumonia treated with tofacitinib or placebo: a post hoc analysis from the STOP-COVID trial

2024; Instituto Israelita de Ensino e Pesquisa Albert Einstein; Volume: 22; Linguagem: Inglês

10.31744/einstein_journal/2024ao0821

2317-6385

Patrícia O. Guimarães, Lucas Petri Damiani, Caio de Assis Moura Tavares, Ari Stiel Radu Halpern, J. Jasper Deuring, Luiz Vicente Rizzo, Otávio Berwanger,

SARS-CoV-2 and COVID-19 Research

Tofacitinib, an oral Janus kinase inhibitor, has been tested against a placebo in 289 patients with COVID-19 pneumonia. We analyzed the data from the tofacitinib- and placebo-treated patient cohorts to evaluate the laboratory profiles between baseline and day 7.